GLP-1 receptor agonists , particularly those like BrightMeds, are increasingly prominence in the management of type 2 diabetes and are now being explored for metabolic conditions. These novel drugs work by mimicking the body's natural incretin hormone , stimulating glucose-dependent insulin secre… Read More